Infinity Biologix LLC

Infinity Biologix LLC, operating as the Sampled Division, is a for-profit limited liability company based in Piscataway, New Jersey, that delivers advanced genomic sequencing, DNA analysis, and biorepository services to federal biomedical research agencies as a prime contractor (61% of recent awards) and as a subcontractor on research initiatives led by academic medical centers. The company holds no SBA set-aside certifications and competes full-and-open across all federal work.

Infinity Biologix's capability portfolio centers on large-scale whole exome and long-read DNA sequencing, epigenomics characterization, RNA analysis, cell line development, biospecimen repository management, and genotyping for cancer research, substance use disorder studies, immunology, and veteran health programs. Representative prime work includes a $4.8 million delivery order from the National Cancer Institute for DNA sequencing support for cancer research under the NCI Genomic Characterization Centers vehicle (awarded September 2026), a $7.8 million delivery order from Veterans Integrated Service Network 1 for long-read sequencing supporting the Million Veteran Program (July 2026), a $2.96 million delivery order from the National Institute on Drug Abuse for the NIDA Center for Genetic Studies (March 2026), and a $4.4 million Department of Veterans Affairs delivery order for genomic analysis services (September 2024).

Customer concentration splits between the National Cancer Institute, the Department of Veterans Affairs, and the National Institute on Drug Abuse. The National Cancer Institute leads on potential value with 3 awards carrying $155.3 million combined, anchored by a $149.2 million multiple-award IDIQ for genome characterization center services awarded January 2025 and running through January 2030. The Department of Veterans Affairs Headquarters accounts for 8 awards totaling $91.5 million in potential value, while Veterans Integrated Service Network 1 carries 4 awards worth $38.6 million. The National Institute on Drug Abuse holds 5 awards valued at $20.8 million. These five customers account for substantially all of Infinity Biologix's potential value. Most recent activity shows growth trajectory: one award in 2022, five in 2023, ten in 2024, nine in 2025, and ten in 2026 through mid-September.

Infinity Biologix holds four significant IDIQs. The $149.2 million NCI Genomic Characterization Centers contract (multiple award, January 2025 to January 2030) has generated seven task orders totaling $54.5 million. A $27.1 million single-award VA IDIQ for long-read sequencing supporting the Million Veteran Program (March 2026 to March 2031) has issued three task orders valued at $11.5 million combined. A $15 million single-award NIDA IDIQ for the Center for Genetic Studies (March 2023 to March 2028) carries two delivery orders totaling $5.7 million. A $158.7 thousand small-business-set-aside USDA Agricultural Research Service contract for next-generation sequencing and bioinformatic analysis (September 2023 to September 2025) has issued one $1 thousand delivery order. The combined potential value across all IDIQs is approximately $192 million.

In subcontract roles, Infinity Biologix provides biospecimen storage and laboratory services to Guidehouse Digital LLC, New TECH Solutions, Inc., and Axle Informatics, LLC on NIDA Developmental Studies Biorepository task orders (most recent September 2025). The company also serves as a subrecipient on federal research grants administered by Rutgers University (NINDS Human Cell and Data Repository U24 renewal, Center for Genomic Studies on Mental Disorders), the Benaroya Research Institute at Virginia Mason (kit production for Immune Tolerance Network clinical trials), and the University of South Florida (Data Coordinating Center for Type 1 Diabetes TrialNet), performing kit production, sample processing, and biorepository work across multiple NIH institutes and programs.

Four awards totaling $14.5 million reach ultimate completion inside the next twenty-four months, creating recompete exposure primarily on VA genomic analysis delivery orders and NCI task orders. Combined potential value across all 44 prime and sub awards is $316.1 million, with $116.1 million obligated to date (37% of potential).